Zura Bio Limited (ZURA)Healthcare | Biotechnology | Henderson, United States | NasdaqCM
4.00 USD
After hours: 4.00 |
Hot Take ↕ | Oct. 10, 2026, 2:31 a.m. EDT
The investment case for Zura Bio is currently bifurcated between a high-risk catalyst play and deteriorating fundamentals. On the surface, the momentum looks compelling: analysts have initiated coverage with 'Outperform' ratings, and insider buying suggests confidence in the long-term thesis. However, the price action tells a different story; the stock is trading significantly below its 50-day and 200-day averages, reflecting persistent selling pressure. The financials are starkly negative, with no earnings, negative free cash flow, and a return on equity of -51%. While the company holds a fortress-like cash position relative to its size, it is burning cash rapidly. The options market confirms this tension, with traders betting on a binary explosion of value or a collapse, rather than a steady climb. Until the Tibulizumab Phase 2 data delivers a definitive positive result, the lack of profitability and the heavy discount to moving averages suggest the stock remains a speculative hold rather than a core investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.098392 |
| AutoETS | 0.098393 |
| AutoTheta | 0.098563 |
| MSTL | 0.098569 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 14.14 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.020 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 383,316,544 |
| Forward P/E | -5.80 |
| Beta | 0.01 |
| Website | https://zurabio.com |
As of Oct. 10, 2026, 2:31 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. Call volume is heavily skewed toward out-of-the-money strikes (7.5 and 10.0), suggesting a hope for a massive rally driven by Tibulizumab trial results. Conversely, put volume is concentrated deep in-the-money (2.5 strike), indicating a fear of a sharp drop if the catalyst fails. The imbalance in implied volatility (IV) between calls and puts suggests the market is pricing in a binary event outcome.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.036269426 |
| Address1 | 1,489 W. Warm Springs Road |
| Address2 | Suite 110 |
| All Time High | 37.55 |
| All Time Low | 0.97 |
| Ask | 5.12 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,340,770 |
| Average Daily Volume3 Month | 1,445,952 |
| Average Volume | 1,445,952 |
| Average Volume10Days | 2,340,770 |
| Beta | 0.009 |
| Bid | 2.93 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.065 |
| City | Henderson |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.0 |
| Current Ratio | 12.9 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 4.12 |
| Day Low | 3.9451 |
| Display Name | Zura Bio |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -92,689,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.922 |
| Enterprise Value | 178,182,544 |
| Eps Current Year | -0.8 |
| Eps Forward | -0.69 |
| Eps Trailing Twelve Months | -1.12 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.1437 |
| Fifty Day Average Change | -1.1437001 |
| Fifty Day Average Change Percent | -0.22234969 |
| Fifty Two Week Change Percent | 3.6269426 |
| Fifty Two Week High | 7.44 |
| Fifty Two Week High Change | -3.44 |
| Fifty Two Week High Change Percent | -0.4623656 |
| Fifty Two Week Low | 3.15 |
| Fifty Two Week Low Change | 0.8499999 |
| Fifty Two Week Low Change Percent | 0.26984122 |
| Fifty Two Week Range | 3.15 - 7.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,679,405,400,000 |
| Float Shares | 50,707,030 |
| Forward Eps | -0.69 |
| Forward P E | -5.7971015 |
| Free Cashflow | -48,821,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 40 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 4.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18924 |
| Held Percent Institutions | 0.87871003 |
| Implied Shares Outstanding | 95,829,137 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-03-21 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada. |
| Long Name | Zura Bio Limited |
| Market | us_market |
| Market Cap | 383,316,544 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1783060399 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -116,445,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 413,981,871 |
| Number Of Analyst Opinions | 6 |
| Open | 3.98 |
| Operating Cashflow | -77,546,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Phone | 702 825 9872 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.0 |
| Post Market Time | 1,791,837,593 |
| Previous Close | 4.0 |
| Price Eps Current Year | -5.0 |
| Price Hint | 4 |
| Price To Book | 1.9370459 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.571 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 4.12 |
| Regular Market Day Low | 3.9451 |
| Regular Market Day Range | 3.9451 - 4.12 |
| Regular Market Open | 3.98 |
| Regular Market Previous Close | 4.0 |
| Regular Market Price | 4.0 |
| Regular Market Time | 1,791,835,200 |
| Regular Market Volume | 1,606,911 |
| Return On Assets | -0.31232 |
| Return On Equity | -0.51007 |
| Sand P52 Week Change | 0.17318833 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 95,829,137 |
| Shares Percent Shares Out | 0.09770001 |
| Shares Short | 9,365,853 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 11,098,438 |
| Short Name | Zura Bio Limited |
| Short Percent Of Float | 0.1305 |
| Short Ratio | 5.44 |
| Source Interval | 15 |
| State | NV |
| Symbol | ZURA |
| Target High Price | 26.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 18.0 |
| Target Median Price | 18.0 |
| Total Cash | 205,134,000 |
| Total Cash Per Share | 2.141 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.315425 |
| Two Hundred Day Average Change | -1.3154249 |
| Two Hundred Day Average Change Percent | -0.24747315 |
| Type Disp | Equity |
| Volume | 1,606,911 |
| Website | https://zurabio.com |
| Zip | 89,014 |